Navigation Links
Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
Date:6/28/2010

e are two major types of diabetes: type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder involving the body's immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer insulin regularly to control their blood glucose levels.

About Otelixizumab

Otelixizumab is a targeted T cell immunomodulator being developed for the treatment of type 1 diabetes and other autoimmune diseases. Otelixizumab targets CD3, a T lymphocyte receptor involved in normal cell signaling. Otelixizumab has not yet been approved for marketing. Data suggest that the antibody may work in patients with type 1 diabetes who have residual beta cells by blocking the function of effector T cells that mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T cells that are understood to protect against effector T cell damage, thus preserving the beta cells' ability to make insulin.

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses.  The company also has three pre-clinical candidates, TRX518, TRX585 and TRX385, that enhance immune responses and as such are being evaluated fo
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... FREMONT, Calif. , June 30, 2015 ... and specialty medicine, continues to grow and add customers ... than 40% of the 62 CTSAs awarded by the ... clinical research information management. This is among the largest ... "Our presence in the CTSA community keeps growing ...
(Date:6/30/2015)... way for people to keep their family safe, while also ... being introduced to the world via an Indiegogo crowdfunding ... which needs to be raised in order to bring the ... was inspired by the many scenarios people face in their ... While medical alert bracelets have been around for years, they ...
(Date:6/30/2015)... -- A new report released today from the Institute of ... and training opportunities to reduce barriers to the provision ... rates of CPR and AED use by bystanders remain ... States even though evidence indicates that its ... Cross strongly supports the IOM,s recommendation to encourage training ...
Breaking Medicine Technology:Velos continues adding CTSA customers - 40% now use Velos products 2Amyko Propels Medical Alert Bracelets Into the Modern Era 2New Recommendations in Cardiac Arrest Protocol Advocate for Increased CPR and AED Training to Improve U.S. Survival Rates 2New Recommendations in Cardiac Arrest Protocol Advocate for Increased CPR and AED Training to Improve U.S. Survival Rates 3New Recommendations in Cardiac Arrest Protocol Advocate for Increased CPR and AED Training to Improve U.S. Survival Rates 4
... Inc. announced today that it has received FDA 510(k) clearance ... Generator powers the Stretta® System for treatment of Gastroesophageal Reflux ... Incontinence or Bowel Control Disorder (BCD). "Today,s ... investment and design efforts by Mederi. The goal of the ...
... ClinOps is a specialized contract research organization with ... biostatistics and specialized clinical services. Emphusion targets development ... when these services are a key to success. ... effective immediately. "Through acquisition and internal ...
Cached Medicine Technology:Mederi Therapeutics Announces Receipt of FDA 510(k) Clearance for the MDRF1 Radiofrequency Generator 2ClinOps to Change Name to Emphusion 2
(Date:7/1/2015)... ... ... Thule Atmos X4 offers protection with minimal bulk. At the Thule Test Center™, ... Due to its Bi-ComponentArmor and ShockStop corners, it passed Thule’s 2 meter drop test, ... The Thule Atmos X4 has also been designed with function in mind. The ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Nutritional Products ... of nutritional and beauty products, recently attended the 2015 ECRM Diet, Vitamin & Sports ... in the retail industry. The ECRM trade show allows companies the chance ...
(Date:7/1/2015)... ... July 01, 2015 , ... First Harvest ... a web-based resource where legal cannabis startups can interact with corporate ... and medical marijuana advocates looking to strategically enter and capitalize on growing and ...
(Date:7/1/2015)... and Copiague, NY (PRWEB) , ... July 01, ... ... provider of physical therapy and rehabilitation clinics throughout New York and New Jersey, ... York, incorporating it into its portfolio of state-of-the-art clinics. At this most recent ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... specializes in Middle eastern, Persian and Mediterranean foods and groceries. Persianbazzar.com has recently ... time for the BBQ season, http://persianbazzar.com added great product lines such ...
Breaking Medicine News(10 mins):Health News:NPI Meets With Top Retail Figures at ECRM Conference 2Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 2Health News:First Harvest Financial Partners in Launch of Legal Medical Cannabis Documentary Initiative 3Health News:Professional Physical Therapy Acquires Copiague’s South Bay Sports & Physical Therapy, P.C. 2Health News:Persian Bazzar Now Announces the Addition of Golden Star Food and Kitchenware to their website. 2Health News:Persian Bazzar Now Announces the Addition of Golden Star Food and Kitchenware to their website. 3
... More than one in four elderly Americans lacked the capacity ... life, according to a study of 3,746 people to be published ... Those who had advance directives - including living wills or ... wanted most of the time, says lead author Maria Silveira, M.D., ...
... Guidelines based on national data point to those heart ... News) -- Who,s most at risk when undergoing the ... U.S. study may have come up with some answers ... the odds of death after angioplasty, also known as ...
... Orange, Calif., March 31, 2010 UC Irvine ... Center have again earned the Gold Seal of ... and accrediting body. Joint Commission certification recognizes ... accepted nationwide as benchmarks for superior patient care. ...
... ... , ... 31, 2010 -- Pat Heyward Canes, a new provider of fashion forward walking canes ... and women ranging from classic to whimsical. Made from performance materials, the canes can ...
... genetic blueprint for humans , WEDNESDAY, March 31 (HealthDay News) ... scientists muse on how far they,ve come and how far ... of the genome draft in 2001 permanently altered the scientific ... to come, according to scientists writing in the April 1 ...
... ... the world to AMD Alliance International,s first global film competition aimed at raising awareness of ... world for people over 50. AMD Alliance International (AMDAI) announced the winners of the contest ... (PRWEB) March ...
Cached Medicine News:Health News:More than one-quarter of elderly patients lack decision-making capacity at death 2Health News:More than one-quarter of elderly patients lack decision-making capacity at death 3Health News:New Insights Into Who's At Risk With Angioplasty 2Health News:New Insights Into Who's At Risk With Angioplasty 3Health News:Medical center's heart failure, stroke programs recertified by Joint Commission 2Health News:Pat Heyward Canes Unveils New Stylish Walking Cane Collection Just in Time for Mother's Day 2Health News:Human Genome Turns 10 2Health News:Human Genome Turns 10 3Health News:Winners Announced from AMD Alliance International Film Contest 2Health News:Winners Announced from AMD Alliance International Film Contest 3Health News:Winners Announced from AMD Alliance International Film Contest 4
... The SC-Acufix anterior cervical plate system ... a patented, integrated swivel, which provides for ... and prevents bone screw disengagement or backout. ... a secondary locking screw. Simply implant your ...
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
... consisting of one part only, is made of ... compressed Polyamide may be rotated and moved as ... sizes and shapes, as well. Moreover they secure ... in caudal direction, which is one of the ...
VG1 ALIF (Anterior) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
Medicine Products: